Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design
ABSTRACT: Background: Intranasal administration is among the most effective alternatives to deliver drugs directly to the brain and prevent first-pass metabolism. Venlafaxine-loaded liposomes are biocompatible carriers that enhance transport qualities over the nasal mucosa. Objective: This research...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Current Therapeutic Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0011393X23000231 |
| _version_ | 1827591722785308672 |
|---|---|
| author | Sulekha Khute, MPharm Rajendra K. Jangde, PhD, MPharm |
| author_facet | Sulekha Khute, MPharm Rajendra K. Jangde, PhD, MPharm |
| author_sort | Sulekha Khute, MPharm |
| collection | DOAJ |
| description | ABSTRACT: Background: Intranasal administration is among the most effective alternatives to deliver drugs directly to the brain and prevent first-pass metabolism. Venlafaxine-loaded liposomes are biocompatible carriers that enhance transport qualities over the nasal mucosa. Objective: This research aimed to develop, formulate, characterize, and observe the prepared formulation. Methods: The formulation was developed using the thin-film hydration technique. The response surface plot interrelationship between three independent variables are lipid, cholesterol and polymer and four dependent variables such as particle size, percentage entrapment efficiency, and percentage drug release were ascertained using the Box-Behnken design. Results: The drug-release chitosan-coated liposomes were reported to have a particle size distribution, entanglement efficiency, and 84%, respectively, of 191 ± 34.71 nm, 94 ± 2.71% and 94 ± 2.71%. According to in vitro investigations, liposomes as a delivery system for the nasal route provided a more sustained drug release than the oral dosing form. Conclusions: The intranasal administration of venlafaxine liposomal vesicles effectively enhanced the absolute bioavailability, retention time, and brain delivery of venlafaxine. |
| first_indexed | 2024-03-09T01:36:44Z |
| format | Article |
| id | doaj.art-f3cc1df5d3e345b88dfeee197055712a |
| institution | Directory Open Access Journal |
| issn | 0011-393X |
| language | English |
| last_indexed | 2024-03-09T01:36:44Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Therapeutic Research |
| spelling | doaj.art-f3cc1df5d3e345b88dfeee197055712a2023-12-09T06:04:08ZengElsevierCurrent Therapeutic Research0011-393X2023-01-0199100714Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental DesignSulekha Khute, MPharm0Rajendra K. Jangde, PhD, MPharm1University Institute of Pharmacy, Pt Ravishankar Shukla University, Chhattisgarh, IndiaAddress correspondence to: Rajendra K. Jangde, PhD, MPharm, University Institute of Pharmacy, Pt Ravishankar Shukla University, Raipur 492010, Chhattisgarh, India.; University Institute of Pharmacy, Pt Ravishankar Shukla University, Chhattisgarh, IndiaABSTRACT: Background: Intranasal administration is among the most effective alternatives to deliver drugs directly to the brain and prevent first-pass metabolism. Venlafaxine-loaded liposomes are biocompatible carriers that enhance transport qualities over the nasal mucosa. Objective: This research aimed to develop, formulate, characterize, and observe the prepared formulation. Methods: The formulation was developed using the thin-film hydration technique. The response surface plot interrelationship between three independent variables are lipid, cholesterol and polymer and four dependent variables such as particle size, percentage entrapment efficiency, and percentage drug release were ascertained using the Box-Behnken design. Results: The drug-release chitosan-coated liposomes were reported to have a particle size distribution, entanglement efficiency, and 84%, respectively, of 191 ± 34.71 nm, 94 ± 2.71% and 94 ± 2.71%. According to in vitro investigations, liposomes as a delivery system for the nasal route provided a more sustained drug release than the oral dosing form. Conclusions: The intranasal administration of venlafaxine liposomal vesicles effectively enhanced the absolute bioavailability, retention time, and brain delivery of venlafaxine.http://www.sciencedirect.com/science/article/pii/S0011393X23000231AntidepressantIntranasalLiposomeOptimizationVenlafaxine |
| spellingShingle | Sulekha Khute, MPharm Rajendra K. Jangde, PhD, MPharm Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design Current Therapeutic Research Antidepressant Intranasal Liposome Optimization Venlafaxine |
| title | Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design |
| title_full | Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design |
| title_fullStr | Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design |
| title_full_unstemmed | Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design |
| title_short | Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design |
| title_sort | optimization of nasal liposome formulation of venlafaxine hydrochloride using a box behnken experimental design |
| topic | Antidepressant Intranasal Liposome Optimization Venlafaxine |
| url | http://www.sciencedirect.com/science/article/pii/S0011393X23000231 |
| work_keys_str_mv | AT sulekhakhutempharm optimizationofnasalliposomeformulationofvenlafaxinehydrochlorideusingaboxbehnkenexperimentaldesign AT rajendrakjangdephdmpharm optimizationofnasalliposomeformulationofvenlafaxinehydrochlorideusingaboxbehnkenexperimentaldesign |